Developing Non-Laboratory Cardiovascular Risk Assessment Charts and Validating Laboratory and Non-Laboratory-Based Models
References
Global health estimates: Deaths by cause, age, sex and country, 2000–2016 . Geneva World Heal Organ; 2016.- Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: A report from the American Heart Association. Circulation. 2015; 131: e29–322. DOI: 10.1161/CIR.0000000000000152
- Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England). 2012; 380: 2095–128. DOI: 10.1016/S0140-6736(12)61728-0
- Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017; 70: 1–25. DOI: 10.1016/j.jacc.2017.04.052
- Sarrafzadegan N, Mohammadifard N. Cardiovascular Disease in Iran in the Last 40 Years: Prevalence, Mortality, Morbidity, Challenges and Strategies for Cardiovascular Prevention. Arch Iran Med. 2019; 22.
- Farshad Sharifi MD, Delavari A. The most prevalent causes of deaths, DALYs, and geriatric syndromes in Iranian elderly people between 1990 and 2010: Findings from the global burden of disease study 2010. Arch Iran Med. 2015; 18: 462.
- World Health Organization (WHO). Technical package for cardiovascular disease management in primary health care: Evidence-based treatment protocols. Report; 2018.
- Karmali KN, Persell SD, Perel P, Lloyd-Jones DM, Berendsen MA, Huffman MD. Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev; 2017. DOI: 10.1002/14651858.CD006887.pub4
- Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: A review for clinicians. J Am Coll Cardiol. 2009; 54: 1209–27. DOI: 10.1016/j.jacc.2009.07.020
- Kaptoge S, Pennells L, De Bacquer D, et al. World Health Organization cardiovascular disease risk charts: Revised models to estimate risk in 21 global regions. Lancet Glob Heal. 2019; 7: e1332–45.
- D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: The Framingham heart study. Circulation. 2008; 117: 743–53. DOI: 10.1161/CIRCULATIONAHA.107.699579
- Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J. 2003; 24: 987–1003. DOI: 10.1016/S0195-668X(03)00114-3
- Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) study. Circulation. 2002; 105: 310–5. DOI: 10.1161/hc0302.102575
- Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63: 2935–59. DOI: 10.1016/j.jacc.2013.11.005
- Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: The ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007; 93: 172–6. DOI: 10.1136/hrt.2006.108167
- Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: Prospective open cohort study. Br Med J. 2007; 335: 136–41. DOI: 10.1136/bmj.39261.471806.55
- Hajifathalian K, Ueda P, Lu Y, et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): A pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol. 2015; 3: 339–55. DOI: 10.1016/S2213-8587(15)00081-9
- Ueda P, Woodward M, Lu Y, et al. Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: A pooled analysis of prospective cohorts and health surveys. Lancet Diabetes Endocrinol. 2017; 5: 196–213. DOI: 10.1016/S2213-8587(17)30015-3
- Beswick AD, Brindle P, Fahey T, Ebrahim S. A systematic review of risk scoring methods and clinical decision aids used in the primary prevention of coronary heart disease. R Coll Gen Pract [GRA]. 2008; 4: 105. DOI: 10.1002/14651858.CD006887
- Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: The NHANES I Follow-up Study cohort. Lancet. 2008; 371: 923–31. DOI: 10.1016/S0140-6736(08)60418-3
- Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH. Cost-effectiveness analysis of hypertension guidelines in South Africa: Absolute risk versus blood pressure level. Circulation. 2005; 112: 3569–76. DOI: 10.1161/CIRCULATIONAHA.105.535922
- Sarrafzadegan N, Hassannejad R, Marateb HR, et al. PARS risk charts: A 10-year study of risk assessment for cardiovascular diseases in Eastern Mediterranean Region. PLoS One. 2017; 12:
e0189389 . DOI: 10.1371/journal.pone.0189389 - Azizi F, Rahmani M, Emami H, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Sozial-Und Präventivmedizin. 2002; 47: 408–26. DOI: 10.1007/s000380200008
- Sarraf-Zadegan N, Sadri G, Malek-Afzali H, et al. Isfahan Healthy Heart Programme: A comprehensive integrated community-based programme for cardiovascular disease prevention and control. Design, methods and initial experience. Acta Cardiol. 2003; 58: 309–20. DOI: 10.2143/AC.58.4.2005288
- Sarrafzadegan N, Talaei M, Sadeghi M, et al. The Isfahan cohort study: Rationale, methods and main findings. J Hum Hypertens. 2011; 25: 545–53. DOI: 10.1038/jhh.2010.99
- Talaei M, Sarrafzadegan N, Sadeghi M, et al. Incidence of cardiovascular diseases in an Iranian population: The Isfahan cohort study. Arch Iran Med. 2013; 16: 138–44.
- Sarrafzadegan N, Hassannejad R, Roohafza H, et al. A 10-year Isfahan cohort on cardiovascular disease as a master plan for a multi-generation non-communicable disease longitudinal study: Methodology and challenges. J Hum Hypertens; 2018. DOI: 10.1038/s41371-018-0126-2
- Khalili D, Hadaegh F, Soori H, Steyerberg EW, Bozorgmanesh M, Azizi F. Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: The Tehran Lipid and Glucose Study. Am J Epidemiol. 2012; 176: 177–86. DOI: 10.1093/aje/kws204
- Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206–52. DOI: 10.1161/01.HYP.0000107251.49515.c2
- Abudukeremu N, Pan S, Ma Y, et al. The optimal cutoff point of waist-to-hip ratio for screening Uyghur population aged 35 years and over at high-risk of cardiovascular diseases in Xinjiang. Zhonghua Xin Xue Guan Bing Za Zhi. 2015; 43: 173–8.
- Song B, Zhang G, Zhu W, Liang Z. ROC operating point selection for classification of imbalanced data with application to computer-aided polyp detection in CT colonography. Int J Comput Assist Radiol Surg. 2014; 9: 79–89. DOI: 10.1007/s11548-013-0913-8
- Harrell FE,
Jr , Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361–87. DOI: 10.1002/(SICI)1097-0258(19960229)15:4<;361::AID-SIM168>3.0.CO;2-4 - D’agostino RB, Nam B-H. Evaluation of the performance of survival analysis models: Discrimination and calibration measures. Handb Stat. 2003; 23: 1–25. DOI: 10.1016/S0169-7161(03)23001-7
- D’Agostino RB, Pencina MJ, Massaro JM, Coady S. Cardiovascular disease risk assessment: Insights from Framingham. Glob Heart. 2013; 8: 11–23. DOI: 10.1016/j.gheart.2013.01.001
- Sepanlou SG, Malekzadeh R, Poustchi H, et al. The clinical performance of an office-based risk scoring system for fatal cardiovascular diseases in north-east of Iran. PLoS One. 2015; 10: 1–12. DOI: 10.1371/journal.pone.0126779
- Zhao D, Liu J, Xie W, Qi Y. Cardiovascular risk assessment: A global perspective. Nat Rev Cardiol. 2015; 12: 301–11. DOI: 10.1038/nrcardio.2015.28
- Liu J, Hong Y, D’Agostino RB, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-provincial Cohort Study. J Am Med Assoc. 2004; 291: 2591–9. DOI: 10.1001/jama.291.21.2591
- Panagiotakos DB, Fitzgerald AP, Pitsavos C, Pipilis A, Graham I, Stefanadis C. Statistical modelling of 10-year fatal cardiovascular disease risk in Greece: The HellenicSCORE (a calibration of the ESC SCORE project). Hell J Cardiol. 2007; 48: 55–63.
- World Health Organization (WHO).
Global health estimates: Deaths by cause, age, sex and country, 2000–2015 . Geneva World Heal Organ; 2016.
DOI: https://doi.org/10.5334/gh.890 | Journal eISSN: 2211-8179
Language: English
Submitted on: Jul 28, 2020
Accepted on: Aug 20, 2021
Published on: Sep 2, 2021
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2021 Razieh Hassannejad, Marjan Mansourian, Hamidreza Marateb, Mohammad Reza Mohebian, Thomas Andrew Gaziano, Rodney T Jackson, Emanuele Di Angelantonio, Nizal Sarrafzadegan, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.